Greenwich Lifesciences (NASDAQ:GLSI) is a biopharmaceutical enterprise focused on the development and commercialization of therapeutics for breast cancer patients. The core of its operations lies in advancing GP2, an immunotherapy designed to prevent the recurrence of breast cancer following surgery. With a clear objective to enhance survival rates and quality of life for breast cancer sufferers, the company leverages cutting-edge scientific research to push the boundaries of treatment possibilities. Greenwich Lifesciences is dedicated to bringing novel, life-saving therapies to market, aiming to transform the landscape of cancer care for women worldwide.